Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jan 13, 2011

Premium

Title: Modulation of Cytokine Signaling Regulators and Applications for Immunotherapy

Patent Number: 7,868,158

Filed: June 23, 2005

Lead Inventor: Si-Yi Chen, Baylor College of Medicine

The invention, the patent's abstract states, "relates to regulation of antigen presentation by cytokine signaling regulators in antigen presenting cells, such as dendritic cells. The invention provides methods of modulating antigen presentation through modulation of cytokine signaling regulators, such as SOCS, SHP, or PIAS. The … invention provides vaccines and therapies in which antigen presentation is enhanced through modulation of cytokine signaling regulators … [as well as] a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens."

The patent specifically claims the use of siRNAs targeting "any one or more of a suppressor of cytokine signaling."


Title: Modulation of Cytokine Signaling Regulators and Applications for Immunotherapy

Patent Number: 7,868,159

Filed: Jan. 19, 2006

Lead Inventor: Si-Yi Chen, Baylor College of Medicine

"The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell," the patent's abstract states. The invention also "provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators … [and] a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens."

The patent specifically claims siRNAs that inhibit A20 expression.


Title: Compositions and Methods for Inhibiting Expression of Anti-Apoptotic Genes

Patent Number:
7,868,160

Filed: July 18, 2008

Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

The invention relates to "a double-stranded ribonucleic acid for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene," the patent's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition, and methods for inhibiting the expression of an anti-apoptotic gene in a cell."


Title: Methods for Producing Interfering RNA Molecules in Mammalian Cells and Therapeutic Uses for Such Molecules

Application Number: 20110003307

Filed: Sept. 14, 2010

Lead Inventor: John Rossi, City of Hope

The invention, the patent application's abstract states, comprises "methods for producing interfering RNA molecules in mammalian cells. …Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided."


Title: Multiple-Promoter Expression Cassettes for Simultaneous Delivery of RNAi Agents

Application Number: 20110003378

Filed: March 12, 2010

Lead Inventor: Petrus Roelvink, Benitec

The invention, the patent application's abstract states, "provides multiple-promoter expression cassettes for simultaneous delivery of RNAi, preferably to mammalian cells in vivo."


Title: siRNA Targeting Apolipoprotein B

Application Number: 20110003713

Filed: July 12, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, composition, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for ApoB."


Title: siRNA Targeting Beta Secretase

Application Number: 20110003714

Filed: Aug. 17, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," according to the patent application's abstract. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE."


Title: Single-Stranded Extended Dicer-Substrate Agents and Methods for the Specific Inhibition of Gene Expression

Application Number: 20110003881

Filed: June 25, 2010

Inventor: Bob Brown, Dicerna Pharmaceuticals

"The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double-stranded nucleic acid in an amount effective to reduce expression of a target gene in a cell," the patent application's abstract states. "The dsNAs of the invention possess a single-stranded extension — in most embodiments, the single-stranded extension comprises at least one modified nucleotide and/or phosphate backbone modification. Such single-stranded extended Dicer-substrate siRNAs were demonstrated to be effective RNA inhibitory agents compared to corresponding double-stranded DsiRNAs."


Title: RNAi Modulation of Aha and Therapeutic Uses Thereof

Application Number: 20110003882

Filed: Sept. 7, 2010

Lead Inventor: Rainer Constien, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of an Aha gene comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene," the patent application's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell."


Title: Treating Oncogenic Ras-Driven Cancers

Application Number: 20110003887

Filed: Jan. 9, 2009

Lead Inventor: Christopher Counter, Duke University

"Oncogenic Ras-driven cancer is treated with [an] agent by interrupting pathway comprising activation of Akt by oncogenic Ras; activated Akt causing phosphorylation of eNOS at S1177 site of eNOS to provide activated eNOS in cancer cells; and activated eNOS causing activation of wildtype Ras by nitrosylation thereof at C118 to provide GTP-bound activated wildtype H and N Ras," the patent application's abstract states. "L-NAME can be orally administered to interrupt this pathway. Wortmannin can be administered intravenously to interrupt this pathway. Novel siRNAs are disclosed useful to interrupt said pathway."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.